Sign in
Taking peoplePhase 4

Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators

Key facts

Who runs it
University of Sao Paulo General Hospital
Where
Brazil1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
200 people, planned
Started
2 Dec 2025
Expected to end
30 Jul 2028
Type of study
Interventional
Treatments tested
  • Recombinant Zoster Vaccine (RZV)
Record updated
11 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Adults aged 18 years or older
  • Diagnosis of an autoimmune rheumatic disease (such as rheumatoid arthritis, systemic lupus erythematosus, axial spondyloarthritis, psoriatic arthritis, systemic sclerosis, Sjögren syndrome, idiopathic inflammatory myopathies, or primary systemic vasculitis) according to validated classification criteria
  • Clinical stability at the time of enrollment, defined as no change in disease-modifying therapy or corticosteroid dose in the preceding four weeks and no evidence of infection or disease flare
  • Current use of hydroxychloroquine or sulfasalazine in monotherapy for at least three months prior to inclusion
  • Can be under prednisone use of 5mg/week
  • Ability and willingness to comply with study procedures and follow-up visits
  • Provision of written informed consent

Who cannot take part

  • Previous vaccination with recombinant zoster vaccine (RZV)
  • History of herpes zoster or varicella infection within 12 months before enrollment
  • Concomitant use of systemic immunosuppressive therapy including but not limited to methotrexate, mycophenolate mofetil, azathioprine, cyclophosphamide, biologics, or JAK inhibitors
  • Acute febrile illness or active infection at the time of vaccination
  • Known hypersensitivity to any component of the recombinant zoster vaccine
  • History of Guillain-Barré syndrome
  • Any condition that, in the investigators' judgment, could interfere with study participation or interpretation of results
  • Use of glucocorticoids >5mg/week
  • Pregnancy or breastfeeding

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This interventional phase IV clinical trial will evaluate the efficacy, immunogenicity and safety of the adjuvanted recombinant herpes zoster vaccine (RZV) in adults with autoimmune rheumatic diseases (ARDs) receiving immunomodulatory monotherapy. Humoral immune response will be quantified by anti-glycoprotein E (anti-gE) antibody titers. Patients will receive two doses of RZV. Outcomes include seroconversion and geometric mean titers six weeks after completion of the vaccination schedule, persistence of antibody titers at one year, and incidence of confirmed herpes zoster during follow-up.

The group in the trial

  • Immunomodulator MonotherapyTreatment being tested

    Participants with autoimmune rheumatic diseases who are clinically stable and receiving monotherapy with hydroxychloroquine or sulfasalazine will receive two doses of the recombinant zoster vaccine (RZV, Shingrix) administered intramuscularly on Day 0 and Day 42. Immunogenicity will be evaluated through anti-glycoprotein E antibody titers at baseline, six weeks, and one year after vaccination. Safety, disease activity, and incidence of herpes zoster will be monitored throughout follow-up.

    Treatment: Recombinant Zoster Vaccine (RZV)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy, Immunogenicity, and Safety of the Recombinant Herpes Zoster Vaccine (RZV) in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators
Record updated
11 March 2026